Turn Therapeutics Inc TTRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
-
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
-
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
-
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
-
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
Trading Information
- Previous Close Price
- $10.07
- Day Range
- $9.70–10.50
- 52-Week Range
- $2.57–26.50
- Bid/Ask
- $9.08 / $12.00
- Shares Outstanding
- 30.37M
- Market Cap
- $297.60M
- Volume/Avg
- 70,574 / 76,695
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 2
- Website
- https://www.turntherapeutics.com
Valuation
|
Metric
|
TTRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 425.86 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TTRX
|
|---|---|
Quick Ratio | 1.17 |
Current Ratio | 1.19 |
Interest Coverage | −40.42 |
Quick Ratio
TTRX
Profitability
|
Metric
|
TTRX
|
|---|---|
Return on Assets (Normalized) | −66.05% |
Return on Equity (Normalized) | −270.54% |
Return on Invested Capital (Normalized) | −138.45% |
Return on Assets
TTRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|mh#pwJ | LOCK|@$x#N | $138B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%P!>B$ | LOCK|@y<W | $85B | |||
| argenx SE ADR
ARGX
| LOCK|GG@KZ@ | LOCK|y&m | $65B | |||
| Moderna Inc
MRNA
| LOCK|!CG?M? | LOCK|<? | $58B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$#hwkL< | LOCK|gL | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$%Td^VK | LOCK|RMdhZ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|nc^gTMf | LOCK|CP@W | $28B | |||
| BioNTech SE ADR
BNTX
| LOCK|QQ<X?! | LOCK|jl | $26B | |||
| Incyte Corp
INCY
| LOCK|sDXG#$@ | LOCK|^&j | $26B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|C%T?<# | LOCK|>$ | $16B |
United States